DataMEDS AI non-binding LOI would leave public holders ~10.5% after share issuance
DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent dated October 19, 2026, with EOS, Scilex, Datavault AI, HealthBridge Advisors and others to acquire QLPM intellectual property, expand a Datavault AI license, and take a controlling interest in Tollo Health, paid in company stock. The filing says existing public stockholders are expected to hold about 10.5% after closing, so the deal would substantially dilute current shareholders. Closing still requires definitive agreements, stockholder and Nasdaq approvals, and other conditions.
Key points
- Target post-closing ownership: EOS 14.9%, Scilex 14.9%, Datavault 19.9%, Fortitude 5%, HBA and THI 24.9%, REBOOT 9.9%; existing public holders about 10.5%
- Closing requires a liability threshold of not more than $2,000,000 and stockholder and Nasdaq approvals
- Company agreed to reimburse Scilex, Datavault and EOS up to $250,000 in legal fees, payable at Closing
- Exclusivity runs through November 30, 2026; Gerald Commissiong to serve as Interim Co-Chief Executive Officer
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.